Conversely, hypoxic areas of HNSCC tumors were found to have reduced EGFR expression (27), possibly due to degradation of EGFR by the hypoxia-induced protein PHD-3 (28), and this was proposed as a putative mechanism of resistance to anti-EGFR therapies. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.